Damora Therapeutics (DMRA) EPS (Weighted Average and Diluted) (2021 - 2026)
Damora Therapeutics (DMRA) reported EPS (Weighted Average and Diluted) of -$0.62 for Q1 2026, up 67.71% on a YoY basis from -$0.37 in Q1 2025, and down 105.71% quarter-over-quarter from $10.86 in Q4 2025.
Damora Therapeutics (DMRA) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Damora Therapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.62 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 67.71% year-over-year to -$0.62; the trailing twelve-month figure through Mar 2026 stood at $5.28 (up 134.15% YoY), and the FY2025 full-year result was $3.98, up 121.48% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.62, down from $10.86 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $10.86 in Q4 2025, with the low at -$7.5 in Q3 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.88 across 5 years, with a median of -$1.92 in 2025.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) plunged 1288.89% — and 2025, when it jumped 307.65%.
- Damora Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.55 in 2022, then sank by 970.91% to -$5.89 in 2023, then gained by 11.21% to -$5.23 in 2024, then soared by 307.65% to $10.86 in 2025, then slumped by 105.71% to -$0.62 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.62 (Q1 2026), $10.86 (Q4 2025), and -$2.36 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | -0.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.62 |
| Dec 31, 2025 | 10.86 |
| Sep 30, 2025 | -2.36 |
| Jun 30, 2025 | -2.60 |
| Mar 31, 2025 | -1.92 |
| Dec 31, 2024 | -5.23 |
| Sep 30, 2024 | -3.39 |
| Jun 30, 2024 | -4.92 |
| Mar 31, 2024 | -5.05 |
| Dec 31, 2023 | -5.89 |
| Sep 30, 2023 | -7.50 |
| Jun 30, 2023 | -0.41 |
| Mar 31, 2023 | -0.51 |
| Dec 31, 2022 | -0.55 |
| Sep 30, 2022 | -0.54 |
| Jun 30, 2022 | -0.67 |
| Mar 31, 2022 | -0.67 |
| Dec 31, 2021 | -0.53 |
| Sep 30, 2021 | -0.50 |